March 2020

Newsletters

Message from the Executive Director

Dear Friends and Families,

The world has changed a great deal since our last Newsletter. The COVID19 pandemic is creating unprecedented challenges in our daily lives. This may be physical health, mental health, economic, or social. New terms like social distancing and self-isolation have entered our vocabulary. For the rare disease community, the health risks and potential complications can be high and additional challenges to medical supplies, medical appointments, and care services may have already been encountered by some. Stress levels are exacerbated for everyone, and this is especially noted in rare disease families who are already faced with higher stressors on a daily basis.

We are proud to have a Scientific Advisory Board working on the front lines is hospitals across the country. We are especially proud of our NNPDF Board Chair, Dr. Justin Hopkin, who is working tirelessly in his capacity as a physician at Rochester University Medical Center.

NNPDF is here for you. Now more than ever, it is vital that we support one another and support our community. We will continue to fight for access to treatments and to carry your voice to the FDA. We will continue to provide family services programs for you, such as our upcoming webinar on Self-Care: Taking Care of You in Challenging Times, which will include a guided meditation. Watch for other programs over the next few weeks designed to create virtual gathering to connect with one another and decompress.

We know that everyone is wondering whether our annual Family Support & Medical Conference will still take place in early July. We are monitoring the COVID19 situation closely and realize that plans are in flux right now. We believe that it is important for our Niemann-Pick community to have the opportunity to come together in-person each year for our Family Support & Medical Conference. We know that our clinical and family services sessions provided at our Conference are important to you, and moreso, the shared experience of simply being together with friends and those who “just get it” is invaluable.

The health and safety of our families is our primary concern. We are following the Centers for Disease Control (CDC) recommendations and consulting with our clinicians and how the virus impacts gatherings, travel, our families and the conference. We are currently monitoring our July date as well as looking at alternate dates that may be possible. We will continue to assess the situation and update you in a few weeks with any new information regarding the status of the conference.  

On an exciting note, NNPDF has recently begun preparing to conduct a survey of the U.S., Niemann-Pick disease community to further understand the patient and healthcare provider experience in Niemann-Pick as it relates to health insurance knowledge, coverage, as well as the burdens experienced by patients and their families pertaining to access of medications, services and devices. This is one of several advocacy campaigns prioritized for the Niemann-Pick community over the next 2 years. It will be the most comprehensive survey of the Niemann-Pick health insurance landscape to be conducted in the U.S. and will allow us to better support you.

And speaking of Supporting One Another, I hope that you’ll take a moment to build a pyramid and be part of our #NNPDFPyramidChallenge2020! From now through May, post and share your creative pyramid on social pages. Go big or go small. Use #NNPDFPyramidChallenge2020 and @NNPDF in your caption to be entered in a drawing for one of three $50 Amazon Gift Cards! You can enter as many times as you like! Don’t forget to challenge your friends to “Do or Donate $20” to the NNPDF to help support Niemann-Pick families. Remember to tag #NNPDFPyramidChallenge2020 and @NNPDF.


Warm wishes,

 

 

Joslyn Crowe,
Executive Director
[email protected]

NNPDF Pyramid Challenge 2020

Looking for something fun to do to support your Niemann-Pick Community and raise awareness of Niemann-Pick disease? Join the NNPDF Pyramid Challenge 2020 and show us how YOU pyramid!

From now through May, post and share your creative pyramid on social pages. Go big or go small. Use #NNPDFPyramidChallenge2020 and @NNPDF in your caption to be entered in a drawing for one of three $50 Amazon Gift Cards! Enter as many times as you like!

Challenge your friends to “Do or Donate $20” to the NNPDF to help support Niemann-Pick families. Remember to tag #NNPDFPyramidChallenge2020 and @NNPDF.

NPD community… Show us how YOU pyramid!

NNPDF Family Support & Medical Conference

Friends,

We are monitoring the COVID19 situation closely and realize that plans are in flux right now. We believe that it is important for our Niemann-Pick community to have the opportunity to come together in-person each year for our Family Support & Medical Conference. We know that our clinical and family services sessions provided at our Conference are important to you, and moreso, the shared experience of simply being together with friends and those who “just get it” is invaluable.

The health and safety of our families is our primary concern. We are following the Centers for Disease Control (CDC) recommendations and consulting with our clinicians and how the virus impacts gatherings, travel, our families and the conference. We are currently monitoring our July date as well as looking at alternate dates that may be possible. We will continue to assess the situation and update you in a few weeks with any new information regarding the status of the conference.  

Please stay safe and follow the recommended healthcare guidance on COVID19.  As always, we are available for any questions.

Taking Care of You: Self Care in Challenging Times

Are you searching for manageable ways to take some time to care for yourself especially during moments of stress and uncertainty?

Please join NNPDF and NTSAD as we jointly present the upcoming forum Taking Care of You: Self-Care in Challenging Times led by Shoshanna Hecht, LCSW, on Wednesday, April 1, 2020 at 2:00 pm EST/11:00 am PST via Zoom Webinar.

This community forum will include practical tips on manageable, every day self-care, a guided meditation, and time for Q&A.

Shoshanna Hecht is an Executive and Personal Coach based in New York City, with previous experience of over 10 years as a clinical therapist on the west coast. Shoshanna also leads guided meditations to boost confidence while reducing stress, self-doubt, and overwhelm. They can be found both on her website and on the Meditation Studio App named one of Apple’s 10 Best Apps of the Year.

 

Volunteers Needed

Thank you to those of you that have shown interest in volunteering for the NNPDF! Your time is invaluable to our NPD community. We are currently collecting resumes and letter of interest from those interested in volunteering skills and time to assist with focus groups, committee teams and even as a Board member. If you are interested in becoming a NNPDF volunteer, please let us know at [email protected] and we will follow up with you with the process for applying.

Please send all letters of interest by April 15th.

In the Spotlight

Tell us a bit about yourself, such as where do you live and what do you enjoy doing
I go by “Dee”. I am one of six children, and the only one to be ‘gifted’ with NPC. As a teenager I used to re-build car engines and street race. I am the mother of one and the “Nonna” of one. I used to love crafting and scrapbooking.  

When did receive your diagnosis? What led you to diagnosis?
In 2005 the neurologist I was seeing for migraines noted that I had some slurred speech and some minor gait issues. This disease is insidious for very late on-set. In 2011, I was struck with Bell’s Palsy, but it never totally resolved, sort of began my downfall. It wasn’t until a gap of about 18 months of not seeing that neurologist and him recognizing that something was really wrong that my diagnosis began. I was first diagnosed with Spino-cerebellar Ataxia – by MRI showing cerebellar atrophy and simultaneously by my speech therapist. What kind of SCA led to genetic testing. The first panel was inconclusive and suggested Sialadosis – but only one allele in an autosomal recessive disease. I was referred to NIH, had an exome sequencing, inconclusive. Finally, I was referred to the geneticist at Walter Reed (my husband is retired military). The geneticist also works at NIH with one of the doctors who works in the Undiagnosed Diseases Program. In May of 2018 I was evaluated by the UDP – 42 vials of blood, untold scans, pokes, testing in 4 days. Results were provided in Aug 2018, I have NPC1, only one allele, but the oxysterols are there to provide diagnosis. So, at age 59 I was diagnosed with a disease that hits infants, children, and if diagnosed late, teens.

What were the first steps you took after diagnosis?
After diagnosis I met with the doctor who leads the NPC program at NIH and was entered in a natural history study, more test, etc. Thank the Lord for the Interwebs. I was able to research the disease, and learn more about it.

How did you learn about NNPDF?
The Interwebs, what more to say.

What caused you to get involved with NNPDF initially and how has being an NNPDF member benefited your family?
As an adult onset patient, I wanted to know more – for my own understanding. Now having seen other patients and families, I see we are all in this together. What helps one, helps all.

What changes have you seen in the Niemann-Pick environment over the past few years?
I haven’t been involved long enough to recognize the changes. However, if you look at the literature, you will see that five years ago, the general message was that NPC was a rare debilitating disease, and everyone had passed on by age 40. Today I’m aware of at least three clinical trials that are improving symptoms, quality of life, and reducing the impact of this disease.

What are your hopes for the future for yourself and for the Niemann-Pick community?
I just completed a phase one clinical trial. Before the trial, I would choke on food or drink at least once per day, often more. Particulate pneumonia is a leading cause of death in NPC patients. After seven doses, at two-week intervals, I am down to choking and coughing about once per week. My speech is also noticeably improved. I am now looking to extend access to the treatment drug. I just need to deal with symptom regression waiting on those infusions.

As for the community, I see the family and those afflicted are united and supportive. I’d like to see the same in the research and medical community.

NNPDF Research Fellowship Applications

We are excited to announce the NNPDF Research Fellowships are open for applications. The Peter G. Penchev Niemann-Pick Type C Research Fellowship and the Edward H. Schuchman ASMD Research Fellowship are 1-year awards intended for early-stage researchers. These awards support young scientists in pursuit of independent hypotheses and encourage scholarly development about Niemann-Pick disease.

Niemann-Pick disease research is one of the pillars of our mission and we are proud that since 1993, NNPDF has funded 52 grants and 18 fellowships totaling over $4,000,000. Our fellowships and grants have contributed to the identification of disease-causing genes, insights into the pathogenesis of NPC1 & NPC2, support of the NPC cat model at a critical juncture, and development of an assay for newborn screening. Many former grantees and fellows have remained active contributors in the Niemann-Pick disease space.

Contact [email protected] with questions.

Application deadline is June 1, 2020

Rare Disease Week on Capitol Hill Summaries

Rare Disease Week on Capitol Hill took place in Washington DC during the last week of February, where rare disease advocates were given the opportunity to meet with Members of Congress and to learn about policy updates and best practices for successful advocacy. A special Thank You to Margo Frey, Havi Martinez, Anne OConnor Smith, and Shannon Reedy for attending this event on behalf of you, the Niemann-Pick community.

Click below to read the 

Rare Disease Week on Capitol Hill took place in Washington DC during the last week of February, where rare disease advocates were given the opportunity to meet with Members of Congress and to learn about policy updates and best practices for successful advocacy. A special Thank You to Margo Frey, Havi Martinez, Anne OConnor Smith, and Shannon Reedy for attending this event on behalf of you, the Niemann-Pick community.

Click below to read the summaries of their learnings and experiences.

NNPDF Launches Important Community Survey

Survey will be the most comprehensive of the Niemann-Pick insurance landscape conducted in the US

The NNPDF has recently begun preparing to conduct a survey of the U.S, Niemann-Pick disease community to further understand the patient and healthcare provider experience in Niemann-Pick as it relates to health insurance knowledge, coverage, as well as the burdens experienced by patients and their families pertaining to access of medications, services and devices.

This is one of several advocacy campaigns prioritized for the Niemann-Pick community over the next 2 years. The survey will identify health insurance usage, access, and barriers across the country. The survey will also allow us to better understand where the community may need more tools or assistance in understanding the complexities of health insurance. The data gathered from this national survey will provide a credible quantitative platform for NNPDF when speaking with legislators, key opinion leaders, and media about access to medications, pricing, economic impact, or legislative reform. This is the most comprehensive survey of the Niemann-Pick health insurance landscape to be conducted in the U.S.

We are excited to work with Engage Health, Inc., a health research firm on this project. The firm is led by Patti Engel who brings over 25 years of experience in orphan and specialty products to her work and has developed similar tools for other rare disease communities. Engage Health, Inc. has a long history of conducting market research and PRO research in the rare disease space. Ms. Engel was the keynote speaker at the NNPDF Family Support & Medical Conference in 2019 and spoke to challenges & realities for the Niemann-Pick community during the regulatory process and post-approvals.

The survey will open to the Niemann-Pick community for participation in late spring/early summer and will consist of an online survey followed by a phone interview. The data gathered in the survey will be published and shared publicly once complete.

NNPDF Community Update Webinar Series

Join us for our Community Update webinar series upcoming events! We have a fantastic line up for you. Visit our Upcoming Webinars webpage for all webinar information.

Community Update Webinar Series featuring Newborn Screening
Monday, April 20, 2020 | Click here to register!

Community Update Webinar Series featuring Mallinckrodt
Monday, April 27, 2020 | Click here to register!

Community Update Webinar Series featuring Sanofi Genzyme
Wednesday, May 6, 2020 | Click here to register!

Community Update Webinar Series featuring IntraBio
Sunday, May 17, 2020 | Click here to register!

INPDR Update

The INPDR would like to take this opportunity to wish all our friends and families in the NNPDF community well. We hope you are all keeping safe and healthy and making use of any support available. If the INPDR shows us anything, it’s that we’re stronger together so please keep in touch. The work of the INPDR continues despite the challenges we now face because of the COVID-19 pandemic.

If you haven’t been following the progress of the INPDR recently, now is the time to take notice.

We have made some very exciting changes to the Registry over the last year, which will improve the quality and quantity of data held in the registry, as well as opportunities to collaborate with the Niemann-Pick disease community and key stakeholders, including clinicians, researchers, regulators and industry.

The electronic data capture (EDC) system has been migrated to a new host, OpenApp Ltd, based in Dublin, Ireland, which has included redeveloping the Clinician Reported Database and Patient Reported Database to be more user friendly, secure and insightful.

The work we are doing will make sure the INPDR supports the development of treatments, improved understanding and diagnosis and better quality of care – all through harnessing the power of patient data and experience.

We also have a new Registry Manager in place, Dr Conan Donnelly, who brings with him a wealth of skills, including a research background and direct experience of managing patient disease registries. We welcome Conan to the Registry Management Team as he will enhance the knowledge and specialisms of our strong team. Please expect to see a lot more of him over the coming months.

The INPDR website has also been updated and you can now connect with us on Facebook @INPDR Twitter @inpdr_tweets and LinkedIn . We had been planning on attending several events this year. As is the case for many, this is no longer possible, but we are still making our presence known and taking part online where the option is available. The INPDR have always recognised how technology can support the work we do and enable the Niemann-Pick disease network – this has never been so well demonstrated as it is now.

You may already know that the Patient Reported Database has been out of action while we made these important changes. It is now back up and running so we will be directly contacting patients and their families who have already signed up to the Patient Reported Database to reactivate their accounts. If you already have an account, please look out for our emails and keep an eye on our social media channels for updates.

As part of launching the new website and EDC system, we will also be running a campaign to improve understanding of the INPDR, the short- and long-term benefits for the community and encourage more patients and their families to sign up and share their data either through the clinician reported database and/or the patient reported database.

The NNPDF continue to be highly valued supporters of the Registry and the INPDR will be working with them on a few projects, including regular updates in the NNPDF newsletter and a webinar, so please look out for them. We will also be updating the information on the NNPDF website so if you have any thoughts about what you would find useful, please get in touch with Ange Wilson ([email protected]).

The INPDR is a global gateway to a lasting legacy so your participation is as valued now as it’s always been.

Clinical Trial Updates

Clinical trials are currently in progress to study and develop treatments for ASMD and NPC. The NNPDF posts new information regarding clinical trial updates as soon as it is received. Visit our Clinical Trials web page for up to date information on all clinical trials.

Updates from Cyclo Therapeutics:
Cyclo Therapeutics announces Positive Safety Profile of its drug Trappsol® Cyclo™ in the treatment of Niemann-Pick disease Type C. Click here for complete announcement.

Cyclo Therapeutics announces positive feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick disease Type C1s. Click here for complete announcement.

Updates from IntraBio:
IntraBio receives Fast Track Designation from FDA for IB1001 treatment of NPC. Click here for complete announcement.

IntraBio announces extension phase for NPC accepted in the United States. Click here for complete announcement.

Update from Orphazyme:
A message from Orphazyme has been shared to the global community of patients, family members and healthcare providers impacted by the corona virus pandemic (COVID-19). Click here for complete announcement.

Therapeutic Updates

Gene therapy is an experimental technique that uses genes to treat or prevent diseases that have no cure. This promising technique may allow doctors to treat a disorder by inserting a gene into a patient’s cells instead of using drugs or surgery. Visit our Gene Therapy web page for up to date information on all gene therapy updates.

Update from Evox Therapeutics:
Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration. Click here for complete announcement.

Fundraising & Awareness Opportunities

Contributions through fundraising by NNPDF members, families and friends are used to provide services and information to individuals and families affected by NPD, as well as supporting research into finding treatments. Please continue to host and support NPD fundraisers. Awareness Events promote awareness to the general public about Niemann-Pick disease. Click here to view current and past fundraising and awareness events.

Facebook Fundraisers

THANK YOU to those of you who have already hosted a Facebook Fundraiser! Are you interested in hosting? It is a great opportunity to raise awareness and funds for the NNPDF. If you are hosting a Facebook fundraiser please email the NNPDF Central Office at [email protected] to let us know.

Kate Wills, Miss Urbana’s Outstanding Teen 2020

Dreams for Dillon – Inspiring young people to use their gifts and talents for good

Kate is an Urbana resident and a sophomore at Urbana High School. She was crowned Miss Urbana’s Outstanding Teen 2020 this past November and is now on a journey to become Miss Maryland’s Outstanding Teen 2020 and Miss America’s Outstanding Teen 2020. Kate has a passion for dance and loves performing with the Urbana Dance Studio. She is planning to study medicine and to ultimately obtain a profession as a pediatrician.

Kate’s platform is Dreams for Dillon, where she hopes to raise awareness of Niemann-Pick disease, raise funds for the people working toward a cure, all while sharing the message that not everyone has the same abilities and gifts, so they should take advantage of their own gifts and talents and use them to be their best self and to give back to others. Kate’s friend Dillon Papier didn’t have that opportunity because the Niemann-Pick disease took his abilities from him. An excerpt  from her platform reads, “As Miss Maryland’s Outstanding Teen, I will have the opportunity to reach a wider audience, build greater awareness, and increase the likelihood of finding a cure for kids like Dillon all while spreading the very important message that all young people should use their gifts and talents to make the world a better place and be their best self.” Kate is excited for the year ahead as she educates others about how they can make a difference and inspire those in her community to believe that their voice matters.

Kate will be competing in Miss Maryland’s Outstanding Teen 2020 (June) and Miss America’s Outstanding Teen 2020 (August). The NNPDF wishes all the best to Kate in her upcoming endeavors!

Jamberry Niemann-Pick disease Nail Wraps

Show your support in the fight against Niemann-Pick disease with these custom Jamberry nail wraps. 30% of all sales will be donated to the National Niemann-Pick disease Foundation for family support services. Click here for ordering details. Available year round.

Have you hosted a fundraiser for NNPDF recently?

Send us your photos and we’ll share them and details from your event in upcoming newsletters!

Upcoming Events

Check out our Upcoming Events page.

Stay Connected With Us

A quick reminder that if you are not receiving our NNPDF monthly newsletter via email or have recently changed your address or email, please click here to join us or to update your information.

Supporting one another. Supporting our community.

February 2020

Newsletters

Message from the Board Chair

NNPDF Community,

Recently NNPDF Executive Director, Joslyn Crowe, and I attended the annual WORLD (We’re Organizing Research on Lysosomal Diseases) scientific meeting. This 16th annual meeting has grown to be the largest of its kind in the world with over 2000 attendees. This is my third WORLD meeting, and the focus on Niemann-Pick was significantly higher than previous years.  

Dr. Melissa Wasserstein spoke about her NIH-sponsored, comprehensive newborn screening pilot program “ScreenPlus.” This study will screen newborns in several NY hospitals for approximately nine lysosomal storage diseases including both ASMD and NP-C. The NNPDF will be an active participant in this pilot, providing support to newly diagnosed patients and families.  Pam Andrews from the Firefly Fund and I are members of the Community Advisory Board. We anticipate this pilot to be very helpful as we work to expand newborn screening for Niemann-Pick diseases. A presentation by the Firefly Fund on its NPC Newborn Screening Working Group and the “ScreenPlus” program will be part of the NNPDF Community Update Webinar Series.

In the NP-C space, there were posters highlighting clinical data on several investigational compounds (adrabetadex, arimoclomol, and Trappsol Cyclo) that are currently being studied through FDA-approved clinical trials in the U.S.  Cyclo Therapeutics, Mallinckrodt, and Orphazyme will be sharing information on their clinical programs during the upcoming Community Updates Webinar Series. In addition, Dr. Marc Patterson presented biomarker data in NP-C patients receiving arimoclomol.

In the ASMD space, Dr. George Diaz presented preliminary data from the pediatric ASCEND trial. Dr. Margaret McGovern’s team presented data on the natural history of ASMD. Dr. Melissa Wasserstein delivered a symposium on ASMD diagnosis and disease burden, and Dr. Ed Schuchman spoke about ceramide as it pertains to the pathophysiology in ASMD during his symposium. Sanofi will also be sharing information on their clinical program in our webinar series.

Shaun Bolton reported on data from the first 6 years of the International Niemann-Pick disease Registry (INPDR). Interest in the INPDR within the rare disease community continues to grow because of its unique design: entirely patient-owned and global. Your participation will be critically important in maintaining and expanding the value of our registry. The NNPDF will continue to champion the expansion of the registry in the U.S. We will be sharing more information in the coming months about how you can ensure you get enrolled in both the Patient and Clinical arms of the registry.

Joslyn and I were able to meet with the scientific, clinical, and industry leaders in our community. We will be reporting back to the NNPDF and INPDA boards in the coming weeks. Both of us left the conference with a sense of excitement about the positive results we saw as well as the productive interactions we had. If you have any questions, please don’t hesitate to reach out to me or our NNPDF staff.

Best wishes,

 


Justin Hopkin, MD
NNPDF Board Chair
[email protected]

NNPDF Community Update Webinar Series Launches, featuring Orphazyme

Join us as Orphazyme presents in the NNPDF Community Update Webinar Series on Sunday, February 23rd at 2:00 pm EST/11:00 am PST.

Speakers and panelists for the webinar include Kim Stratton, Orphazyme CEO, Thomas Blaettner, Chief Medical Officer, Molly Painter, President Orphazyme, U.S., Marc Patterson, MD, Professor of Neurology, Pediatrics and Medical Genetics at Mayo Clinic and Regan Sherman, Orphazyme Patient Advocacy Relations Lead.

This will be the first webinar in the 2020 NNPDF Community Update Webinar Series, a series designed to provide hour-long updates on issues impacting U.S. Niemann-Pick disease families, including clinical updates and educational updates on issues relevant to our community. Join us LIVE when possible to see the full webinar—the Question & Answer discussion can only be seen at the live presentation. All webinars in this series will be posted online following the event for viewing at any time throughout the year. Registration is required in advance for each webinar.

Rare Disease Week on Capitol Hill

What is Rare Disease Week on Capitol Hill?
Rare Disease Legislative Advocates (RDLA), a program of the EveryLife Foundation for Rare Diseases, will bring together over 800 patients, caregivers, and others in Washington, DC for a week of events dedicated to empowering patients, families, friends, and healthcare professionals to become legislative advocates. During the week of February 24 – 29, 2020, rare disease advocates will have an opportunity to meet with Members of Congress and to learn about policy updates and best practices for successful advocacy.

Why is Rare Disease Week important to the Niemann-Pick disease community?
As part of the Niemann-Pick community, we are all advocates and our voices matter. Building awareness about rare diseases like Niemann-Pick disease is so important, and Capitol Hill week is a great opportunity for our voices to be heard.

Rare Disease Week is an opportunity for our community to increase awareness, learn about policy updates, and educate our policy makers about the challenges we face, and needs that we share, in living with Niemann-Pick disease.

NNPDF Advocacy Stipend
A limited number of stipends were offered by the NNPDF to Niemann-Pick individuals or caregivers to attend Rare Disease Week on Capitol Hill in Washington, DC from February 24 – 29, 2020. Congratulations to the following stipend recipients: Margo Frey, Gail Koujaian, Anne OConnor Smith, and Shannon Reedy. We are eager to read the summaries of their learnings and experiences in the March issue of the NNPDF Newsletter.

Rare Disease Day – February 29th

To raise awareness for Niemann-Pick disease and Rare Disease Day the NNPDF has created a custom frame for your Facebook profile pictures. Also, please feel free to display and share the NNPDF Rare Disease Day Facebook banner to promote awareness.

To add the NNPDF Rare Disease Day frame to your Facebook profile picture:

  1. Go to facebook.com/profilepicframes and log in to your page.
  2. Search for “NNPDF Rare Disease Day 2020” frame and click selection.
  3. Click “change picture” in the upper right of the frame window to change your photo if desired.
  4. Adjust to fit by using slider at bottom of frame, set duration preferences if desired and click “use as profile picture” button.
  5. You may also do this by selecting “update” on your profile photo from your profile page, select add frame, and search for the “NNPDF Rare Disease Day 2020” frame.

NNPDF Family Support & Medical Conference

Registration details will be coming soon for the 2020 Family Support and Medical Conference! Conference program dates are July 9 – 11, 2020 in San Antonio, Texas, with a SPECIAL EVENT you don’t want to miss on Sunday, July 12th.

Sunday, July 12th, the NNPDF is planning a Family Fun Day at Morgan’s Wonderland, Ultra-Accessible Theme Park. This is a time for families and friends to gather and HAVE FUN in a worry free environment. Morgan’s Wonderland was designed with special-needs individuals in mind and built for everyone’s enjoyment. Morgan’s Wonderland offers 25 ultra-accessible™ attractions, sprawled across a 25-acre oasis of inclusion. From a wheelchair-accessible Ferris wheel to catch-and-release fishing, there is truly something for everyone to enjoy!

The NNPDF has shared an Agenda at a Glance for our conference programming overview. More details will be provided in upcoming days. In the meantime, please include Sunday, July 12th in your family conference travel plans! Click here for more details about Morgan’s Wonderland.

CONFERENCE REGISTRATION OPENING SOON!

Into the Spotlight

Dr. Ed Schuchman

Genetic Disease Foundation – Francis Crick Professor

Vice Chair for Research Department of Genetics & Genomic Sciences Mount Sinai School of Medicine

NNPDF Scientific Advisory Board

Dr. Schuchman is The Genetic Disease Foundation – Francis Crick Professor & Vice Chairman for Research in the Department of Genetics & Genomic Sciences of the Icahn School of Medicine at Mount Sinai in New York. He received his Ph.D. in Human Genetics from Mount Sinai in 1983, and after completing a postdoctoral fellowship in molecular genetics at Yale University, returned to Mount Sinai as a faculty member in 1986. His laboratory has been studying the biology of lysosomal enzymes and storage diseases for over 30 years, resulting in the first isolation of the genes encoding several lysosomal enzymes, including acid sphingomyelinase (ASM), and the first DNA-based screening for ASMD. Based on his work, clinical trials of ERT for ASMD are also underway. He also co-founded Plexcera Therapeutics, where he served as the Chief Scientific Officer and developed the first ERT for Farber disease (acid ceramidase deficiency). Together with his wife, Dr. Calogera Simonaro, Dr. Schuchman also re-purposed a drug called pentosan polysulfate (PPS) for the mucopolysaccharidoses. The National Institutes of Health and other organizations have continuously funded Dr. Schuchman’s research since 1986, and he is the recipient of an NIH MERIT award for his work on ASMD. He has published over 225 peer-reviewed basic research articles and 50 reviews in the area of lysosomal biology and disease, and frequently lectures around the world on these topics.

What inspired you to begin working in the field of Niemann-Pick disease?
I was first inspired to work on Niemann-Pick disease in 1986 as a new faculty member at Mount Sinai when I was introduced to a child with NPC. This left a profound impression on me, and shortly thereafter I began reading about the disease. From this I realized that the biology of NPD was very poorly understood, and that there were only a small handful of laboratories in the world investigating it. Even the relationship of what we now know as ASMD and NPC was not clearly understood at that time. This presented a remarkably interesting scientific challenge to me, and one where I could see that with some hard work and luck my research might make a difference.

What changes have you seen in the field of NP research throughout your career?
Having worked on NPD for over 30 years, the changes I have seen are nothing short of remarkable. As mentioned above, when I first started in this field we still did not have a clear understanding of the difference between ASMD and NPC, and there were no reliable tests to diagnose patients. Of course, the genes had not yet been isolated for either disease, there was no animal model for ASMD (only a mouse model existed for NPC), and no disease specific treatments were being developed. This has all changed, first with the isolation of the genes and identification of mutations, followed by the production of the recombinant ASM and NPC1 proteins, the construction and further development of animal models, and the use of these animal models to evaluate new treatments. Along with these developments came commercial interest and partnerships, which led to clinical trials and has transformed the field of NPD research to where it is today.

How did you come to be involved with the NNPDF?
I first became involved with the NNPDF in the late 1980s, right around the time the organization was being formed and coming into its own. By then my research had begun to focus on ASMD, and as one of the only individuals working on this disease I was in contact with many patients and families from around the world to help educate them about the disease and offer assistance. Many were frustrated because of the small number of family support groups and the lack of information that existed at that time, and in particular the ASMD families often felt alone since most of the groups were focused on NPC and it was very difficult for them to find information and support on ASMD. This led to my early involvement as one of the first scientific advisors to the NNPDF and the NPUK, and later to a large number of the other international NPD family support groups, with the goal of bringing the ASMD and NPC communities under one umbrella.

What do you enjoy the most about your professional role and your volunteer role with NNPDF?
Without a doubt it is coming to know the patients and families and developing long lasting relationships with many of them. This is something that as a laboratory scientist many of us do not have the opportunity to do. I have always found these relationships incredibly motivational to me, and something that I relate to as a father with a child with a chronic disease. I have also felt very satisfied that for the most part the NPD support groups around the world have taken our advice and included ASMD under their umbrellas. I continue to believe that this is extremely important from a support, advocacy and fund-raising perspective, especially for extremely rare diseases such as ASMD and NPC, since there is power in numbers and the NPD community can have much greater influence working together rather than apart.

What do you think the future of NPD looks like?
I strongly believe that we are entering an era where disease-modifying therapies for these diseases will become a reality. However, it is also unlikely that any one therapy will address all aspects of these highly complex diseases, so we will continue to see new research aimed at improving these therapies and examining combinations of drugs in controlled preclinical and clinical trials. This will require continued funding, and for this the NNPDF and other family organizations will continue to play an incredibly important advocacy and educational role. I also believe that newborn screening for these diseases is likely to be implemented, which is important from a treatment perspective but also presents a challenge to understand when treatments should be initiated and to justify this to the reimbursement agencies. This is likely to be an important area of clinical research in the future.

Meeting the Newborn Screening Requirements

The NPC community is engaged in a multi-stakeholder effort to add NPC to newborn screening lists across the country. Since adding any new condition to these lists would mean that any newborn would routinely be screened for a certain disease, it’s essential to demonstrate that the benefit to public health is greater than any burden to a family or to the larger public health system.

The federal government maintains a list of diseases and conditions that they have determined meet the standards for being included. That list, known as the Recommended Uniform Screening Panel or the RUSP, serves as the “Gold Standard” for states across the country that look to the federal government for advice when considering what to add to their own screening lists. In order to be included on the RUSP, a sponsoring organization must complete a nomination form that answers very specific questions regarding a condition’s “readiness” to be added. One of the questions asks for evidence that demonstrates the urgency of treatment. The application reviewers need to know how essential it is to identify a particular condition at birth so that an intervention can take place. Specifically, the RUSP nomination form asks, “How soon after birth must treatment be initiated to be effective?”

For NPC, this is an important and challenging question to answer. While there are several clinical trials ongoing to investigate the efficacy and safety of possible medications to treat NPC, we are still awaiting a first approval in the United States. Related to the gap that exists in an FDA-approved therapy, is the answer to the question of “when to treat.” To help gather the necessary evidence and expert opinion on this matter, the Firefly Newborn Screening Working Group has initiated the help of a Clinical Roundtable. This Roundtable is comprised of experts who are working to gain consensus regarding the timing for initiating treatment for patients positively identified with NPC following newborn screening. It’s important work that the Working Group not only believes will be essential for the quest for newborn screening, but also in the quest to improve clinical care for patients.

NNPDF in Action

2020 WORLDSymposium: Justin Hopkin, Board Chair and Joslyn Crowe, Executive Director recently attended the WORLDSymposium, designed for those around the world interested in learning more about the latest discoveries related to lysosomal diseases. Leading scientists from were selected to present their research findings including NNPDF Scientific Advisory Board members Dr. Melissa Wasserstein, Dr. Marc Patterson, and Dr. Ed Schuchman. Also in attendance were representatives from the INPDA and the INPDR.

2020 StrideBio NPC Awareness Event:
Thank you to StrideBio for hosting NNPDF at their NPC Awareness event. Niemann-Pick families shared stories of their NPC journey with the StrideBio team, and were updated on StrideBio’s work in gene therapy. NNPDF community member presentations were given by the Ferguson, Kingsberry and Marsh families.

Clinical Trial Updates

Clinical trials are currently in progress to study and develop treatments for ASMD and NPC. The NNPDF posts new information regarding clinical trial updates as soon as it is received. Visit our Clinical Trials web page for up to date information on all clinical trials.

Updates from Cyclo Therapeutics:
Cyclo Therapeutics, Inc. announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to NPC1 patients. Click here for complete announcement.

Cyclo Therapeutics, Inc. announced that the last patient has undergone the final assessment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to NPC patients. Click here for complete announcement.

Cyclo Therapeutics, Inc. poster presentation of clinical trial data on Niemann-Pick Type C disease at the 16th Annual WORLDSymposium now available. Click here for complete announcement.

Update from Sanofi Genzyme:
Sanofi announces positive topline results demonstrated by olipudase alfa, the first and only investigational therapy in late-stage development for ASMD. Click here for complete announcement.

Fundraising & Awareness Opportunities

Contributions through fundraising by NNPDF members, families and friends are used to provide services and information to individuals and families affected by NPD, as well as supporting research into finding treatments. Please continue to host and support NPD fundraisers. Awareness Events promote awareness to the general public about Niemann-Pick disease. Click here to view current and past fundraising and awareness events.

Facebook Fundraisers

THANK YOU to those of you who have already hosted a Facebook Fundraiser! Are you interested in hosting? It is a great opportunity to raise awareness and funds for the NNPDF. If you are hosting a Facebook fundraiser please email the NNPDF Central Office at [email protected] to let us know.


Jamberry Niemann-Pick disease Nail Wraps

Show your support in the fight against Niemann-Pick disease with these custom Jamberry nail wraps. 30% of all sales will be donated to the National Niemann-Pick disease Foundation for family support services. Click here for ordering details. Available year round.

Have you hosted a fundraiser for NNPDF recently?

Send us your photos and we’ll share them and details from your event in upcoming newsletters!

Upcoming Events

Check out our Upcoming Events page.

Stay Connected With Us

A quick reminder that if you are not receiving our NNPDF monthly newsletter via email or have recently changed your address or email, please click here to join us or to update your information.

Supporting one another. Supporting our community.

January 2020

Newsletters

Message from the Executive Director

Dear Friends and Families,

As the new year begins, we at NNPDF are working on your behalf to continue the positive community spirit and momentum that with which we ended the year. 

We are excited to announce the NNPDF Advocacy Stipend for Rare Disease Week on Capitol Hill, which will assist Niemann-Pick individuals or caregivers to attend the Rare Disease Week events taking place in Washington DC this February. Details can be found on our website and in this newsletter.

The second issue of the INPDA global newsletter will be published around Rare Disease Day, and we will of course take part, as a national organization, in the rare disease awareness activities throughout the coming weeks.

This February through April we are holding our NNPDF Community Update Webinar Series providing hour-long updates on issues impacting U.S. Niemann-Pick disease families, including clinical updates and educational updates on issues relevant to our community. Join us LIVE when possible to see the full webinar—the Question & Answer discussion can only be seen at the live presentation. All webinars in this series will be posted online following the event for viewing at any time throughout the year. Registration is required in advance for each webinar

Please remember that our Family Services are available to all of our community members, whether you’d like to have a one-on-one discussion with our Family Services Manager, join one of our group activities, or need assistance through our Emergency Hardship Program, we are only a click or phone call away.

With best wishes,

 

 

Joslyn Crowe, MSW, MA
NNPDF Executive Director

NNPDF Advocacy Stipend for Rare Disease Week on Capitol Hill

NNPDF Advocacy Stipend
NNPDF is offering a limited number of stipends for Niemann-Pick individuals or caregivers to attend Rare Disease Week on Capitol Hill in Washington, DC from February 24 – 29, 2020.

What is Rare Disease Week on Capitol Hill?
Rare Disease Legislative Advocates (RDLA), a program of the EveryLife Foundation for Rare Diseases, will bring together over 800 patients, caregivers, and others in Washington, DC for a week of events dedicated to empowering patients, families, friends, and healthcare professionals to become legislative advocates. During the week of February 24 – 29, 2020, rare disease advocates will have an opportunity to meet with Members of Congress and to learn about policy updates and best practices for successful advocacy. Click here for complete information.

Why is Rare Disease Week important to the Niemann-Pick disease community?
As part of the Niemann-Pick community, we are all advocates and our voices matter. Building awareness about rare diseases like Niemann-Pick disease is so important, and Capitol Hill week is a great opportunity for our voices to be heard.

Rare Disease Week is an opportunity for our community to increase awareness, learn about policy updates, and educate our policy makers about the challenges we face, and needs that we share, in living with Niemann-Pick disease.

What is the NNPDF Advocacy Stipend?
The NNPDF Advocacy Stipend for Rare Disease Week on Capitol Hill is intended to help patients and families take part in the events planned by RDLA. A limited number of $500 stipends are available to assist with hotel and travel to the event. Attendees are required to make their own travel arrangements including hotel reservations. Deadline for application is January 30th. For detailed stipend application information click the link below.

NNPDF Rare Disease Day Participation

To raise awareness for Niemann-Pick disease and Rare Disease Day the NNPDF has created a custom frame for your Facebook profile pictures. Also, please feel free to display and share the NNPDF Rare Disease Day Facebook banner to promote awareness.

To add the NNPDF Rare Disease Day frame to your Facebook profile picture:

  1. Go to facebook.com/profilepicframes and log in to your page.
  2. Search for “NNPDF Rare Disease Day 2020” frame and click selection.
  3. Click “change picture” in the upper right of the frame window to change your photo if desired.
  4. Adjust to fit by using slider at bottom of frame, set duration preferences if desired and click “use as profile picture” button.
  5. You may also do this by selecting “update” on your profile photo from your profile page, select add frame, and search for the “NNPDF Rare Disease Day 2020” frame.

NNPDF Family Support & Medical Conference

Mark your calendars for the 2020 Family Support and Medical Conference! Conference program dates are July 9 – 11, 2020 in San Antonio, Texas, with a SPECIAL EVENT you don’t want to miss on Sunday, July 12th.

Sunday, July 12th, the NNPDF is planning a Family Fun Day at Morgan’s Wonderland, Ultra-Accessible Theme Park. This is a time for families and friends to gather and HAVE FUN in a worry free environment. Morgan’s Wonderland was designed with special-needs individuals in mind and built for everyone’s enjoyment. Morgan’s Wonderland offers 25 ultra-accessible™ attractions, sprawled across a 25-acre oasis of inclusion. From a wheelchair-accessible Ferris wheel to catch-and-release fishing, there is truly something for everyone to enjoy!

The NNPDF has posted an Agenda at a Glance for our conference programming overview. More details will be provided in upcoming days. In the meantime, please include Sunday, July 12th in your family conference travel plans! Click here to learn more about Morgan’s Wonderland and all is has to offer.

Firefly’s Newborn Screening Working Group Excited about Seeing 2020

The calendar has turned to 2020 and Firefly’s NPC Newborn Screening Working Group is full of anticipation and excitement about the year ahead.

As we begin the year, Firefly notes the Working Group is set for a full year of activities designed to advance the research supporting adding NPC to newborn screening lists. This includes the launch of the first-ever newborn screening pilot study that will include NPC. This will be the first time anywhere newborns will be screened for NPC. Additionally, the group is poised to raise awareness among even more stakeholders about the importance of including NPC on newborn screening lists. This includes our first presentation at the World Orphan Drug Congress taking place in April. Of course none of this would be possible without the incredible and growing support from our partners in industry, academia, and the nonprofit world. Three years ago it was hard to imagine where our nascent efforts would be today. But, with continued commitments from all, we look forward to making even more progress on our common vision where all newborns are screened for NPC, enabling a diagnosis at birth.

Clinical Trial Updates

Clinical trials are currently in progress to study and develop treatments for ASMD and NPC. The NNPDF posts new information regarding clinical trial updates as soon as it is received. Visit our Clinical Trials web page for up to date information on all clinical trials.

Update from IntraBio:
IntraBio completes NPC clinical trial enrollment. Click here for complete announcement.

Updates from Orphazyme:
Orphazyme announces early access program availability in the U.S. for those living with NPC. A communication from Orphazyme to the U.S. NPC patient/parent community has also been shared which provides some direction for how interested families can obtain information about the program. Click here for complete announcement.

Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C. Click here for complete announcement.

Fundraising & Awareness Opportunities

Contributions through fundraising by NNPDF members, families and friends are used to provide services and information to individuals and families affected by NPD, as well as supporting research into finding treatments. Please continue to host and support NPD fundraisers. Awareness Events promote awareness to the general public about Niemann-Pick disease. Click here to view current and past fundraising and awareness events.

Facebook Fundraisers

THANK YOU to those of you who have already hosted a Facebook Fundraiser! Are you interested in hosting? It is a great opportunity to raise awareness and funds for the NNPDF. If you are hosting a Facebook fundraiser please email the NNPDF Central Office at [email protected] to let us know.

Jamberry Niemann-Pick disease Nail Wraps

Show your support in the fight against Niemann-Pick disease with these custom Jamberry nail wraps. 30% of all sales will be donated to the National Niemann-Pick disease Foundation for family support services. Click here for ordering details. Available year round.

Have you hosted a fundraiser for NNPDF recently?

Send us your photos and we’ll share them and details from your event in upcoming newsletters!

Upcoming Events

Check out our Upcoming Events page.

Stay Connected With Us

A quick reminder that if you are not receiving our NNPDF monthly newsletter via email or have recently changed your address or email, please click here to join us or to update your information.

Supporting one another. Supporting our community.